Equillium - Home

Life is all about balance

Bringing treatments designed to restore the balance of the immune system to patients who hope to restore the balance in their lives.

About EQ504

EQ504 is a potent and selective AhR modulator with a unique, multi-modal, non-immunosuppressive mechanism of action that is complementary to other inflammation and immunology agents.

AhR is critical to barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair and regeneration, while regulating resident immune cells with anti-inflammatory responses.

About Itolizumab

Itolizumab is being developed in multiple severe immuno-inflammatory diseases.

Itolizumab is a clinical-stage, first-in-class immune-modifying monoclonal antibody that targets the CD6-ALCAM signaling pathway to selectively downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response.

Learn About Itolizumab

About Equillium's Multi-Cytokine Inhibitor Platform

First-in-class structured-domain peptides that inhibit multiple disease driving cytokines with applications in numerous inflammatory conditions.

Arising from a proprietary discovery platform, the peptides utilize a novel modality to selectively inhibit multiple disease driving cytokines, while leaving other immune regulatory pathways intact.

Learn About Multi-Cytokine Platform

Our Latest News

View All News

Leaders in Immunobiology

At Equillium, we leverage a deep understanding of immunobiology and its role in disease to pioneer new products for severe autoimmune and inflammatory disorders with high unmet medical need.